This site is intended for healthcare professionals

Sarepta Therapeutics announces FDA approval of Amondys 45 injection for the treatment of Duchenne Muscular Dystrophy in patients amenable to skipping exon 45.

Read time: 1 mins
Last updated:28th Jun 2021
Published:27th Feb 2021
Condition: Duchenne Muscular Dystrophy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest